Matches in SemOpenAlex for { <https://semopenalex.org/work/W2060957071> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- W2060957071 abstract "Central nervous system (CNS) metastases develop in nearly half of patients with advanced melanoma and in 15-20% CNS is the first site of relapse. Median overall survival is short, ranging from two to four months, and one-year survival rate is only 10-15%. THA has been shown to have both anti-angiogenetic and immuno-modulating effects. TMZ is an oral alkylating agent with an excellent oral bioavailability and it is highly lipophillic with an ability to penetrate the blood-brain barrier. TMZ and THA in combination were tested in patients with brain metastases from malignant melanoma.Between June 2004 and February 2007 patients with measurable metastatic melanoma in progression and PS ≤ 1 received TMZ in a dose of 150 mg/m(2) qd for seven days, followed by seven days off therapy and THA in 200 mg qd, both orally administered. Concomitant treatment with steroids was allowed. PBMCs were collected from the last 14 consecutive patients for evaluation of immune parameters.Forty screened patients were eligible and evaluable for response, and 39 were evaluable for toxicity. 25 patients had asymptomatic and 15 symptomatic brain metastases. The toxicity was primarily grade 1-2 with no grade 4 or treatment-related deaths. Four patients had thromboembolic events grade 3. One patient obtained a CR and five a PR in the CNS, while two had CR and four had PR outside CNS. Overall response rate was 17.5%. We found a significant positive correlation between lymphopenia and objective response.The combination treatment was well tolerated but with more frequent thromboembolic events compared to single drug TMZ or THA. The treatment demonstrated activity in CNS as well as outside CNS. The correlation between lymphopenia and objective response needs further investigation." @default.
- W2060957071 created "2016-06-24" @default.
- W2060957071 creator A5006731302 @default.
- W2060957071 creator A5019182013 @default.
- W2060957071 creator A5042696536 @default.
- W2060957071 creator A5051043977 @default.
- W2060957071 creator A5057277696 @default.
- W2060957071 creator A5073102947 @default.
- W2060957071 date "2008-01-01" @default.
- W2060957071 modified "2023-09-28" @default.
- W2060957071 title "A Phase II Study of Thalidomide and Temozolomide in Patients With Brain Metastases From Malignant Melanoma. Lymphopenia Correlates With Response" @default.
- W2060957071 doi "https://doi.org/10.3332/ecancer.2008.91" @default.
- W2060957071 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3234039" @default.
- W2060957071 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22275974" @default.
- W2060957071 hasPublicationYear "2008" @default.
- W2060957071 type Work @default.
- W2060957071 sameAs 2060957071 @default.
- W2060957071 citedByCount "0" @default.
- W2060957071 crossrefType "journal-article" @default.
- W2060957071 hasAuthorship W2060957071A5006731302 @default.
- W2060957071 hasAuthorship W2060957071A5019182013 @default.
- W2060957071 hasAuthorship W2060957071A5042696536 @default.
- W2060957071 hasAuthorship W2060957071A5051043977 @default.
- W2060957071 hasAuthorship W2060957071A5057277696 @default.
- W2060957071 hasAuthorship W2060957071A5073102947 @default.
- W2060957071 hasBestOaLocation W20609570711 @default.
- W2060957071 hasConcept C126322002 @default.
- W2060957071 hasConcept C143998085 @default.
- W2060957071 hasConcept C2777389519 @default.
- W2060957071 hasConcept C2777658100 @default.
- W2060957071 hasConcept C2777910003 @default.
- W2060957071 hasConcept C2779384505 @default.
- W2060957071 hasConcept C29730261 @default.
- W2060957071 hasConcept C31760486 @default.
- W2060957071 hasConcept C502942594 @default.
- W2060957071 hasConcept C509974204 @default.
- W2060957071 hasConcept C71924100 @default.
- W2060957071 hasConcept C90924648 @default.
- W2060957071 hasConceptScore W2060957071C126322002 @default.
- W2060957071 hasConceptScore W2060957071C143998085 @default.
- W2060957071 hasConceptScore W2060957071C2777389519 @default.
- W2060957071 hasConceptScore W2060957071C2777658100 @default.
- W2060957071 hasConceptScore W2060957071C2777910003 @default.
- W2060957071 hasConceptScore W2060957071C2779384505 @default.
- W2060957071 hasConceptScore W2060957071C29730261 @default.
- W2060957071 hasConceptScore W2060957071C31760486 @default.
- W2060957071 hasConceptScore W2060957071C502942594 @default.
- W2060957071 hasConceptScore W2060957071C509974204 @default.
- W2060957071 hasConceptScore W2060957071C71924100 @default.
- W2060957071 hasConceptScore W2060957071C90924648 @default.
- W2060957071 hasLocation W20609570711 @default.
- W2060957071 hasLocation W20609570712 @default.
- W2060957071 hasLocation W20609570713 @default.
- W2060957071 hasLocation W20609570714 @default.
- W2060957071 hasOpenAccess W2060957071 @default.
- W2060957071 hasPrimaryLocation W20609570711 @default.
- W2060957071 hasRelatedWork W1484022485 @default.
- W2060957071 hasRelatedWork W2039289142 @default.
- W2060957071 hasRelatedWork W2039764330 @default.
- W2060957071 hasRelatedWork W2081094155 @default.
- W2060957071 hasRelatedWork W2262493723 @default.
- W2060957071 hasRelatedWork W2361498120 @default.
- W2060957071 hasRelatedWork W2361902531 @default.
- W2060957071 hasRelatedWork W3024838620 @default.
- W2060957071 hasRelatedWork W3032106482 @default.
- W2060957071 hasRelatedWork W4212846356 @default.
- W2060957071 isParatext "false" @default.
- W2060957071 isRetracted "false" @default.
- W2060957071 magId "2060957071" @default.
- W2060957071 workType "article" @default.